News
Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer
Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 PANOVA-3 clinical trial evaluating the safety and efficacy of Tumor Treating Fields
EQS-Adhoc: Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.
Owens & Minor Announces Second Quarter 2023 Earnings Release Date and Conference Call
Owens & Minor, Inc. (NYSE: OMI) plans to release financial results for the second quarter of 2023 on Friday, August 4, 2023, before trading begins on the New York Stock Exchange.
The Company
Sartorius Stedim Biotech SA: Information on Document Availability
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
Sartorius Stedim Biotech SA: Half-year results 2023 of Sartorius Stedim Biotech
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 3, 2023, following the release of its second
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a clinical-stage genomic medicine company and Chroma Medicine, Inc. (Chroma), a genomic medicine company pioneering single-dose epigenetic editing
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2023, on Thursday, August 3
Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate
Pfizer Inc. (NYSE: PFE) today announced data from a Phase 2 study investigating its hexavalent capsular polysaccharide (CPS) conjugate Group B Streptococcus (GBS) vaccine candidate, GBS6, being
Premier, Inc. to Report Fiscal 2023 Fourth-Quarter and Full-Year Results and Host Conference Call on August 22, 2023
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2023 fourth quarter and full year on Tuesday, August 22, 2023, at approximately 6:30 a.m. ET. The
Agilent to Announce Third-Quarter Fiscal Year 2023 Financial Results Aug. 15
Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2023 after the stock market closes on Tuesday, Aug. 15. In addition, the company will host a
Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that full results from the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published
Charles River Laboratories Schedules Second-Quarter 2023 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2023 financial results on Wednesday, August 9th, before the market opens. A conference call has been scheduled
STAAR Surgical to Report Second Quarter Results on August 2, 2023
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the second
Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health
QuidelOrtho to Report Second Quarter 2023 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech completes acquisition of Polyplus
Poxel Announces Upcoming Participation at the H.C. Wainwright 2nd Annual Kidney Conference
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Acadia Healthcare Opens the First of Two Hospitals Developed in Partnership With Geisinger
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the opening of its newest operating joint venture hospital, Geisinger Behavioral Health Center Northeast, located in Moosic
Transgene Receives $15.3 Million from the Sale of Securities Held for Sale
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that it has received $15.3
Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
Sangamo Therapeutics, Inc. (“Sangamo”, Nasdaq: SGMO), a genomic medicine company, today announced it has signed an evaluation and option agreement with Prevail Therapeutics (“Prevail”), a wholly